Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
How would you approach treatment for local chest wall recurrence while on Anastrozole for a postmenopausal woman with ER+ IDC s/p mastectomy?
What systemic therapy would you use?
Related Questions
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?
How do you assess and counsel women with chronic post-lumpectomy or mastectomy pain?
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
What neoadjuvant chemotherapy do you suggest for a rapidly growing triple-negative breast cancer?
When do you recommend preoperative chemotherapy or hormonal therapy for ER+ breast cancer?
What are your top takeaways in Breast Cancer from ESMO 2024?
What adjuvant systemic therapy would you recommend for a premenopausal woman with a germline BRCA mutation who initially presented with locally advanced, HR+, HER2-negative (FISH) IDC, but was later found on surgical pathology to have HR+, HER2+ disease (IHC 3+) after neoadjuvant chemotherapy?
Would you consider adjuvant capecitabine for a patient with triple-negative metaplastic carcinoma who has microinvasive residual disease (ypT1miN0) following neoadjuvant therapy?
What is the preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?
What are your top takeaways in Radiation Oncology from SABCS 2024?